Amy Calistri
Stock of the Month
Stephen Leeb
Income Performance Report
Roger Conrad
The Utility Forecaster
Paul McWilliams
Next Inning

Pro Timer favors oil and gold


Bookmark and Share

By Curtis Hesler, editor The Professional Timing Service

Curtis Hesler Professional Timing ServiceWhere should you invest in 2010? Preferably, you should stick to the heart of the matter and focus on crude oil and gold.

Invest in assets that promise to increase in price as the dollar falls; this will insulate your portfolio from the damage that the ongoing deleveraging process will bring to the stock market and to other paper assets.

It is instructive that although the 10-year yield is rolling over somewhat, having moved down from over 3.80% a few weeks ago to about 3.70% now, it is not breaking sharply lower as it has after past peaks.  Consider also that the 10-year yield is up from 2.20% over the last 12 months. 

There is an emerging trend here. There is a gamble for you if you have fixed income/liquid assets to invest.  The bet is that we will see yields on the 10-year and the shorter maturities much higher by year’s end. The way to play this is to do what may seem like pure folly - sit tight in short term paper. 

Advertisement
Banner

Don’t go overboard trying to maximize yield.  I would stick to as short a term as possible - no more than one year - so that you will have the flexibility to move into T-bills once short term rates begin to run.

I know you don’t get much for liquidity these days.  Don’t fret it.  It makes no sense to augment risk just to get another one percent.  It is best to stay safe. 

I prefer bank CD’s, keeping in mind your FDIC insurance coverage.  Bide your time. You will be glad you did. Thus, for now, stay short term and park your liquidity as safely as possible.

The best capital gain bet this year will be in gold.  While the Street was overly enthusiastic about gold last December, we took some money off the table, anticipating a temporary upside correction in the U.S. dollar and some consequential selling in gold and the mining shares.

This is where the timing aspect comes into play. We have focused on buying, but only at lower prices during a correction. I am looking to Goldcorp (NYSE: GG) and Royal Gold (NYSE: RGLD) which are my top choices in the majors. 

In addition, crude oil is coming off as expected ... finally!  I had been forecasting that a trip back to $70.00 is likely. This outlook is on track. 

Meanwhile, Blackrock Energy and Resources (NYSE: BGR) has been performing very well and can be considered on further weakness. Blackrock gives you a nice diversified approach to energy along with a decent dividend.  At $23.00, it has an indicated yield of 7.00%.

Sometimes the best investment strategy requires a little sitting and waiting. This is one of those times.  Stash your cash and wait for the coming correction to unfold. We are going to see some great buying opportunities this spring.

Learn more about this financial newsletter at The Professional Timing Service.




Banner
News Flash

Linkedin: Professional profits
by Leo Fasciocco, editor Ticker Tape Digest

Online professional network operator Linkedin (LNKD) recently moved above its technical breakout point of $108.53. We now target a move to $138.


Read more...

 

Tap in to water stocks
by Doug Fabian, editor Making Money Alert

As we prepare for the summer heat, water presents a significant investment opportunity -- especially as states such as California and Texas face droughts. The PowerShares Water Resource ETF (PHO) presents one way to invest in water's untapped potential.


Read more...


   

Pax World: High yield exception
by Amy Calistri, editor The Daily Paycheck

I generally prefer closed-end or exchange-traded funds because the fees tend to be lower. But I made a special case for Pax World High Yield Bond (PAXHX); this high-yield bond fund is my only open-ended mutual fund holding.


Read more...

 

Amgen: Biotech DRIP
by Chuck Carlson, editor DRIP Investor

Amgen (AMGN) is one of the oldest and largest players in the biotechnology area. It pioneered the development of products based on advances in recombinant DNA and molecular biology, launching the biotechnology industry’s first blockbuster medicines.


Read more...

 

Fidelity fund expert looks to Japan
by Jim Lowell, editor Fidelity Investor

In my May Marketwatch investment strategy column I noted, “Set against the backdrop of having already been thrown out with the Eurozone’s bathwater, I like Japan’s marketplace overall and, more specifically, their small cap marketplace which caters to domestic counter traffic.”


Read more...

 

MOO: Market Vectors Agribusiness
by Doug Fabian, editor Making Money Alert

Everyone needs food to survive, so wouldn't it be great to make money from it? We can. The global agriculture business provides a fairly stable investment with growth potential. In particular, I am looking at Market Vectors Agribusiness ETF (MOO).


Read more...

 

Celgene: Selloff creates opportunity
by J. Royden Ward, editor Cabot Benjamin Graham Value Letter

Celgene (CELG) develops and assists in the marketing of drugs to treat cancer and infl ammatory diseases. It acquired several companies recently, which will expand its product line and add promising products in various stages of development.


Read more...

 

Senior housing reits for income
by Brian Hicks, editor Wealth Advisory

Omega Healthcare Investors (OHI) and Medical Properties Trust (MPW) caters to the senior housing/assisted living facilities. Given the growing senior population, it makes sense to be somewhat over-exposed to companies that target this market.


Read more...

 

Buffett: Still banking on banks
by Ron Rowland, editor All Star Investor

Wise investors zero in on conflicting data points. Warren Buffett, the wisest investor of all, provided plenty to consider at the Berkshire Hathaway annual meeting. 


Read more...

 

Questcor: 'Exponential demand'
by Dennis Slothower, editor Stealth Stocks

Questcor Pharmaceuticals (QCOR), our latest featured stock of the month, is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions.


Read more...

 



Banner



Close
Select Offer: Schwab Options Market Commentary